Balt Extrusion SAS

Based in France, Balt Extrusion SAS specializes in the development and manufacturing of innovative medical devices that focus on neurovascular interventions, enhancing patient outcomes through advanced solutions. Balt Extrusion SAS, founded in 1977, operates from Montmorency, France, producing medical devices specifically for neurovascular treatments. The company has engaged in two significant deals, with its most recent deal occurring on April 1, 2018. The company was not formed through a merger or carve-out, and there are no known subsidiaries or parent companies.

Balt Extrusion SAS is known for creating and manufacturing medical devices that target neurovascular interventions. The company pioneered one of the first neurovascular intervention devices in 1977 and has expanded its offerings to include solutions for both ischemic and hemorrhagic strokes, as well as products tailored for peripheral embolization. Their products aim to meet the clinical needs of healthcare providers and are utilized by hospitals and medical professionals across North America, Europe, and Asia-Pacific. In the most recent fiscal year of 2023, Balt Extrusion SAS reported a revenue of USD 94.

59 mn and an EBITDA of USD 21. 91 mn. The company generates revenue primarily through direct sales to healthcare providers and partnerships with distributors, with a pricing structure that reflects the specialized nature of their offerings in the medical device market. Balt Extrusion SAS is strategically focused on expanding its product portfolio and geographic presence.

The company is in the process of designing new devices targeted for neurovascular interventions, with plans to launch these products in the upcoming fiscal years. Additionally, Balt aims to enter new markets in Asia-Pacific and South America by 2025. The funding raised in their previous rounds will support these initiatives, ensuring that the company can continue to innovate and meet the growing demand in these regions.